Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
The Doshisha has 5 pending office actions in Chemistry & Materials. The matters involve 5 distinct examiners and 5 distinct art units, showing distribution across separate examination assignments.
RAHMANI, NILOOFAR is the busiest examiner, with 1 pending matter. Counsel should coordinate the portfolio’s chemistry and materials positions while preparing individualized responses for each examination record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 3 (60%) |
| §102 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| MCCARTY, PATRICK M | 1 | 62.4% | +21.4% |
| CHU, YONG LIANG | 1 | 74.9% | +3.2% |
| MCCOLLUM, ANDREA K | 1 | 60.2% | +33.3% |
| LEE, JOHN | 1 | 31.7% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928988 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | MCCOLLUM, ANDREA K | 201d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17928988 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | MCCOLLUM, ANDREA K | 201d overdue |
| 18287183 | CARBON CARRIER FOR FUEL CELL CATALYST AND FUEL CELL CATALYST | MCCARTY, PATRICK M | — |
| 17762924 | Liquid Flow Formation Method and Object Moving Method Using Same | LEE, JOHN | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1774 | 1 |
| 1731 | 1 |
| 1674 | 1 |
| 1794 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702178 | DETOXIFYING AGENT, DETOXIFYING AGENT KIT, AND NOVEL INCLUSION COMPLEX | RAHMANI, NILOOFAR | 1691 | §102 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18287183 | CARBON CARRIER FOR FUEL CELL CATALYST AND FUEL CELL CATALYST | MCCARTY, PATRICK M | 1774 | §103 | Final Rejection | — | Pending | Oct 17, 2023 |
| 18039569 | GOLD-SUPPORTED CARBON CATALYST AND METHOD FOR MANUFACTURING SAME | CHU, YONG LIANG | 1731 | §103 | Final Rejection | 28d | Pending | May 31, 2023 |
| 17928988 | S100A8-INHIBITING PEPTIDE AND DISEASE THERAPEUTIC AGENT CONTAINING SAME | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Final Rejection | 201d overdue | Pending | Dec 01, 2022 |
| 17762924 | Liquid Flow Formation Method and Object Moving Method Using Same | LEE, JOHN | 1794 | §103 | Non-Final OA | — | Pending | Mar 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Doshisha has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Niloofar Rahmani has the most, with 1 of The Doshisha's pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
